Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ZAI Laboratory ADR Representing Ord Shs ZLAB

Healthcare Biotechnology
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.


NDAQ:ZLAB - Post by User

ZAI Laboratory ADR Representing Ord Shs
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(291)
•••
Post by whytestockson Jul 10, 2023 7:30pm
120 Views
Post# 35534540

Zai Lab Announces Acceptance by China's NMPA of the BLA for

Zai Lab Announces Acceptance by China's NMPA of the BLA for
JUST IN: $ZLAB Zai Lab Announces Acceptance by China's NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia GravisSHANGHAI, China and CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China&#x2019;s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for efgartigimod alfa injection (subcutaneous...ZLAB - Zai Lab Announces Acceptance by China's NMPA of the BLA for Efgartigimod Alfa Injection (Subcutaneous Injection) for Patients with Generalized Myasthenia Gravis

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities